During the last session, INmune Bio Inc (NASDAQ:INMB)’s traded shares were 0.41 million, with the beta value of the company hitting 1.78. At the end of the trading day, the stock’s price was $4.75, reflecting an intraday loss of -2.46% or -$0.12. The 52-week high for the INMB share is $14.74, that puts it down -210.32 from that peak though still a striking 6.32% gain since the share price plummeted to a 52-week low of $4.45. The company’s market capitalization is $105.32M, and the average intraday trading volume over the past 10 days was 0.2 million shares, and the average trade volume was 263.94K shares over the past three months.
INmune Bio Inc (NASDAQ:INMB) trade information
INmune Bio Inc (INMB) registered a -2.46% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.46% in intraday trading to $4.75, hitting a weekly high. The stock’s 5-day price performance is -3.06%, and it has moved by -16.96% in 30 days. Based on these gigs, the overall price performance for the year is -54.93%. The short interest in INmune Bio Inc (NASDAQ:INMB) is 3.71 million shares and it means that shorts have 18.08 day(s) to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The consensus price target of analysts on Wall Street is $22, which implies an increase of 78.41% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $22 and $22 respectively. As a result, INMB is trading at a discount of -363.16% off the target high and -363.16% off the low.
INmune Bio Inc (INMB) estimates and forecasts
Statistics show that INmune Bio Inc has underperformed its competitors in share price, compared to the industry in which it operates. INmune Bio Inc (INMB) shares have gone down -44.05% during the last six months, with a year-to-date growth rate less than the industry average at -34.13% against 17.10. In the rating firms’ projections, revenue will decrease -93.98% compared to the previous financial year.
As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 28k and 14k respectively. In this case, analysts expect current quarter sales to shrink by -100.00% and then drop by -100.00% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -5.50%. While earnings are projected to return -37.43% in 2024.
INMB Dividends
INmune Bio Inc is due to release its next quarterly earnings in January. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
INmune Bio Inc (NASDAQ:INMB)’s Major holders
INmune Bio Inc insiders own 28.73% of total outstanding shares while institutional holders control 24.35%, with the float percentage being 34.17%. BLACKROCK INC. is the largest shareholder of the company, while 92.0 institutions own stock in it. As of 2024-06-30, the company held over 0.81 million shares (or 4.5095% of all shares), a total value of $7.17 million in shares.
The next largest institutional holding, with 0.63 million shares, is of VANGUARD GROUP INC’s that is approximately 3.4854% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $5.54 million.
